KineMed to Present Ground-Breaking Human Biomarker Data for the Diagnosis and Treatment of Parkinson’s Disease

Dr. Patrizia Fanara,Vice President, Neuroscience at KineMed, Inc., will present Applying Kinetic Biomarkers to the Diagnosis and Treatment of Parkinsons Disease and Other Neurological Disorders at the 6th Neurodegenerative Conditions Research and Development Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. (www.kinemed.com) announced today that Dr. Patrizia Fanara, Vice President, Neuroscience at KineMed, Inc., will present Applying Kinetic Biomarkers to the Diagnosis and Treatment of Parkinsons Disease and Other Neurological Disorders at the 6th Neurodegenerative Conditions Research and Development Conference on Friday September 14th, in San Francisco, California.

Our unique class of biomarkers track changes in mechanisms that affect the nervous system of living patients. Kinetic markers enable scientists and physicians to define the early stages of neurodegeneration and facilitate the development of successful therapies for Parkinsons and other neurological diseases.

Dr. Fanara will show what can be done with the KineMed platform to advance drug discovery, with examples from CNS research, illustrating how isotopic labeling can be used to study diseases and translate from pre-clinical into human studies.

The presentation will provide an overview of the Companys proprietary biomarker platform, which usesin vivo labeling with deuterated or heavy water, combined with specialized mass spectrometric analysis of biomolecules important in the pathogenesis of the nervous system. Applications of this unique approach in preclinical and clinical research studies will be discussed. Specifically, the presentation will illustrate how deuteriumlabeling patterns of proteins driving neuronal dysfunction can be translated from tissue to body fluids between disease and healthy states.

It is literally thrilling to be able to observe and study what happens to neurons in Parkinsons patients, said Dr. Fanara, Our unique class of biomarkers track changes in mechanisms that affect the nervous system of living patients. Kinetic markers enable scientists and physicians to define the early stages of neurodegeneration and facilitate the development of successful therapies for Parkinsons and other neurological diseases.

The presentation will take place at 1:45 pm on Friday September 14th in the session titled Biomarkers: Translation from Discovery to Clinical, at the San Francisco Hilton, 750 Kearny Street, San Francisco California.

About KineMed, Inc.

KineMed, Inc., is a biomarker discovery and development company based in Emeryville, California. Our biomarkers provide predictive, actionable information to dramatically improve, de-risk and accelerate drug discovery, development and disease management decisions. The Companys proprietary assays reveal dynamic causal processes of disease, rather than isolated molecular targets, and provide precise measures of therapeutic effectiveness on these processes. KineMeds translational assays extract yes/no answers from the complexity of protein dynamics and network biology, addressing treatment questions such as Is this drug right for the patient? and Is the drug working?

KineMeds biomarkers are fully translational from animal to man, seamlessly harmonizing data across pre-clinical and clinical phases of development, through to the diagnosis and management of diseases including fibrotic, metabolic, cardiovascular disease, and cancer.

Link:
KineMed to Present Ground-Breaking Human Biomarker Data for the Diagnosis and Treatment of Parkinson’s Disease